GlaxoSmithKline, the pharmaceutical giant, says it will sell two travel vaccines to a rival for €955m (£822m) as it plans to invest more in cancer treatments.
It sold Rabipur, which is a vaccine against rabies and Encepur, which is to prevent of tick-borne encephalitis, to Bavarian Nordic.
GSK bought the treatments from Novartis in 2015.
Leave a Comment